{"name":"BioMarin Pharmaceutical","permalink":"biomarin-pharmaceutical","crunchbase_url":"http://www.crunchbase.com/company/biomarin-pharmaceutical","homepage_url":"http://www.bmrn.com","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":null,"number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":null,"alias_list":"","email_address":"","phone_number":"","description":"","created_at":"Tue Jan 26 07:09:40 UTC 2010","updated_at":"Wed Aug 18 18:09:17 UTC 2010","overview":"<p>BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company&#8217;s product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include NaglazymeÂ® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; AldurazymeÂ® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and KuvanÂ® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.</p>","image":{"available_sizes":[[[150,33],"assets/images/resized/0007/4854/74854v1-max-150x150.jpg"],[[250,55],"assets/images/resized/0007/4854/74854v1-max-250x250.jpg"],[[317,71],"assets/images/resized/0007/4854/74854v1-max-450x450.jpg"]],"attribution":null},"products":[],"relationships":[],"competitions":[],"providerships":[],"total_money_raised":"$0","funding_rounds":[],"investments":[],"acquisition":null,"acquisitions":[{"price_amount":58500000,"price_currency_code":"USD","term_code":null,"source_url":"http://www.fiercebiotech.com/story/biomarin-snares-orphan-disease-upstart-115m-buyout/2010-08-18?utm_medium=rss&utm_source=rss","source_description":"BioMarin Acquires Huxley Pharmaceuticals, Inc.","acquired_year":2009,"acquired_month":10,"acquired_day":26,"company":{"name":"Huxley Pharmaceuticals","permalink":"huxley-pharmaceuticals","image":null}},{"price_amount":115000000,"price_currency_code":"USD","term_code":null,"source_url":"http://www.fiercebiotech.com/story/biomarin-snares-orphan-disease-upstart-115m-buyout/2010-08-18?utm_medium=rss&utm_source=rss","source_description":" BioMarin snares orphan drug upstart in $115M buyout","acquired_year":2010,"acquired_month":8,"acquired_day":18,"company":{"name":"Zystor","permalink":"zystor","image":{"available_sizes":[[[100,101],"assets/images/resized/0009/8353/98353v1-max-150x150.jpg"],[[100,101],"assets/images/resized/0009/8353/98353v1-max-250x250.jpg"],[[100,101],"assets/images/resized/0009/8353/98353v1-max-450x450.jpg"]],"attribution":null}}}],"offices":[],"milestones":[],"ipo":null,"video_embeds":[],"screenshots":[],"external_links":[]}